A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease
PC Desai, JE Brittain, SK Jones, A McDonald… - Thrombosis research, 2013 - Elsevier
Introduction The contribution of platelet activation to the pathogenesis of sickle cell disease
(SCD) remains uncertain. We evaluated the safety and efficacy of eptifibatide, a synthetic
peptide inhibitor of the αIIbβ3 receptor, in SCD patients during acute painful episodes.
Materials and Methods In this single site, double-blind, placebo-controlled trial, eligible
patients with SCD admitted for acute painful episodes were randomized to receive
eptifibatide or placebo at a ratio of 2: 1. Results Thirteen patients (SS-10, Sβ 0-2, SC-1) were …
(SCD) remains uncertain. We evaluated the safety and efficacy of eptifibatide, a synthetic
peptide inhibitor of the αIIbβ3 receptor, in SCD patients during acute painful episodes.
Materials and Methods In this single site, double-blind, placebo-controlled trial, eligible
patients with SCD admitted for acute painful episodes were randomized to receive
eptifibatide or placebo at a ratio of 2: 1. Results Thirteen patients (SS-10, Sβ 0-2, SC-1) were …